DBV Technologies (NASDAQ:DBVT) Now Covered by StockNews.com

StockNews.com initiated coverage on shares of DBV Technologies (NASDAQ:DBVT) in a report issued on Saturday morning. The firm issued a hold rating on the stock.

A number of other research firms have also recently commented on DBVT. HC Wainwright raised their price target on shares of DBV Technologies from $25.00 to $35.00 and gave the stock a “buy” rating in a report on Thursday, October 24th. JMP Securities reaffirmed a “market outperform” rating and set a $10.00 price target on shares of DBV Technologies in a research note on Friday, January 10th.

DBV Technologies Stock Down 1.4 %

DBVT stock opened at $4.34 on Friday. The company’s fifty day simple moving average is $3.56 and its 200 day simple moving average is $3.86. DBV Technologies has a 12-month low of $2.20 and a 12-month high of $9.49. The firm has a market cap of $89.27 million, a price-to-earnings ratio of -0.96 and a beta of 0.64.

DBV Technologies (NASDAQ:DBVT) last issued its earnings results on Wednesday, November 6th. The company reported ($0.80) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.90) by $1.10. The business had revenue of $1.07 million during the quarter, compared to the consensus estimate of $1.17 million. DBV Technologies had a negative return on equity of 106.07% and a negative net margin of 815.73%. Research analysts expect that DBV Technologies will post -7.05 earnings per share for the current year.

DBV Technologies Company Profile

DBV Technologies SA, a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow’s milk protein allergy and eosinophilic esophagitis.